Evidence map›Paper›PMID 36877443›Full record

ArticleAdvances in therapy2023

Real-World Racial Variation in Treatment and Outcomes Among Patients with Peripheral Artery Disease.

Keith C Ferdinand, Kay Sadik, Richard Browne, Urvi Desai, Patrick Lefebvre, Dominique Lejeune, Malena Mahendran, François Laliberté, Lisa Matay, David G Armstrong

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Enrollment of Historically Underrepresented Groups in Peripheral Arterial Disease Trials: A Systematic Review.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Review
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Keith C FerdinandTulane University School of Medicine, New Orleans, LA, USA.
Kay SadikJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Richard BrowneJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Urvi DesaiAnalysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. Urvi.Desai@analysisgroup.com.ORCID http://orcid.org/0000-0001-5196-7201
Patrick LefebvreGroupe d'analyse, Ltée, Montréal, QC, Canada.
Dominique LejeuneGroupe d'analyse, Ltée, Montréal, QC, Canada.
Malena MahendranGroupe d'analyse, Ltée, Montréal, QC, Canada.
François LalibertéGroupe d'analyse, Ltée, Montréal, QC, Canada.
Lisa MatayAnalysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
David G ArmstrongKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Analysis Group (United States) · USJanssen (United States) · USTulane University · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrior studies have found considerable disparities in prevalence and outcomes for patients with peripheral arterial disease (PAD). This study compared rates of diagnostic testing, treatment patterns, and outcomes after diagnosis of PAD among commercially insured Black and White patients in the United States.

methodsOptum's de-identified Clinformatics

resultsA total of 669,939 patients were identified, with 454,382 White patients and 96,162 Black patients. Black patients were younger on average (71.8 years vs. 74.2 years), but had higher comorbid burden, concomitant risk factors, and CV medication use at baseline. Prevalence of diagnostic testing, revascularization procedures, and medication use was numerically higher among Black patients. Black patients were also more likely than the White patients to receive medical therapy without a revascularization procedure [adjusted odds ratio with 95% confidence interval (CI) = 1.47 (1.44-1.49)]. However, Black patients with PAD had higher incidence of MALE and CV events than White patients [adjusted hazard ratio for composite event (95% CI) = 1.13, (1.11-1.15)]. Except myocardial infarction, the hazards of individual components of MALE and CV events were also significantly higher among Black patients with PAD.

conclusionsResults of this real-world study suggest that Black patients with PAD have higher disease severity at the time of diagnosis and are at increased risk of experiencing adverse outcomes following diagnosis.

Indexed as

Myocardial InfarctionPeripheral Arterial DiseaseComorbidityHumansRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesCardiovascular eventsDiagnostic testingDisparitiesMedical managementPeripheral artery diseaseRaceTreatment patternsVariation

Identifiers

PMID36877443
PMCPMC10070216
OpenAlexW4323294350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.